02236nas a2200277   4500000000100000008004100001260001300042653003000055653001100085653002300096653001200119653003000131100001100161700001300172700001200185700001200197700001500209700001200224700001200236700009700248245006400345300001100409490000700420520151700427022001401944       2000                            d  c2000 Nov10aDrug Therapy, Combination10aHumans10aLeprostatic Agents10aleprosy10aWorld Health Organization1 aGoto M1 aIshida Y1 aGidoh M1 aNagao E1 aNamisato M1 aIshii N1 aOzaki M1 aAd hoc committee on treatment guideline and judgement of cure, Japanese Leprosy Association 00a[Guideline for the treatment of Hansen's disease in Japan].  a157-770 v693 a<p>Ad hoc committee of Japanese Leprosy Association recommends standard treatment protocol of leprosy in Japan, which is a modification of World Health Organization's multidrug therapy (WHO/MDT, 1997). For paucibacillary (PB) leprosy, 6 months treatment by rifampicin and dapsone (MDT/PB) is enough. However, for high bacterial load multibacillary (MB) leprosy, 12 months treatment seems insufficient. Thus, (A) For MB with bacterial index (BI) > or = 3 before treatment, 2 years treatment by rifampicin, dapsone and clofazimine (MDT/MB) is necessary. (A-1) When satisfactory decrease of BI (BI value decrease > or = 2 steps, or final BI < 3) is obtained after completion of 2 years MDT/MB, maintenance therapy by dapsone and clofazimine is recommended until BI negativity and loss of active lesions. (A-2) When BI decrease is not satisfactory (BI value decrease < 2 steps, or final BI > or = 3), MDT/MB should be continued until BI negativity and loss of active lesions. (B) For MB with BI < 3 or fresh MB (less than 6 months after the onset of the disease) with BI > or = 3, 1 year treatment by rifampicin, dapsone and clofazimine (MDT/MB) is necessary. (B-1) When BI become negative and active lesion is lost within one year, no maintenance therapy is necessary. (B-2) When BI is still positive or active lesion is remaining, additional therapy with MDT/MB for one more year is recommended. Brief summary of diagnosis, purpose of therapy, character of drugs, and prevention of deformity is also described.</p>  a1342-3681